Download full-text PDF

Source
http://dx.doi.org/10.1176/ajp.2007.164.6.843DOI Listing

Publication Analysis

Top Keywords

fda pediatric
4
pediatric advisories
4
advisories changes
4
changes diagnosis
4
diagnosis treatment
4
treatment pediatric
4
pediatric depression
4
fda
1
advisories
1
changes
1

Similar Publications

Deferoxamine Intradermal Delivery Patch for Treatment of a Radiation Therapy Associated Breast Wound.

Ann Case Rep

June 2024

Hagey Laboratory for Pediatric Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.

Purpose: Radiation therapy is used in over 60% of cancer patients and can lead to radiation dermatitis, radiation induced fibrosis, hyperpigmentation, telangiectasias, fat necrosis, and poor wound healing. Deferoxamine (DFO) is an iron-chelating agent that has been used systemically to treat iron overload conditions and more recently been studied to treat radiation fibrosis. Through iron chelation, DFO stabilizes hypoxia inducible factor-1α, driving downstream upregulation of angiogenic factors, and reduces formation of reactive oxygen species, thereby offering a potential therapy for radiation associated chronic wounds.

View Article and Find Full Text PDF

Current Antiviral Therapies and Promising Drug Candidates against Respiratory Syncytial Virus Infection.

Virol Sin

January 2025

Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China; Research Unit of Critical Infection in Children, Chinese Academy of Medical Sciences, 2019RU016, China. Electronic address:

Respiratory syncytial virus (RSV) is one of the most common viruses leading to lower respiratory tract infections (LRTIs) in children and elderly individuals worldwide. Although significant progress in the prevention and treatment of RSV infection was made in 2023, with two anti-RSV vaccines and one monoclonal antibody approved by the FDA, there is still a lack of postinfection therapeutic drugs in clinical practice, especially for the pediatric population. In recent years, with an increasing understanding of the pathogenic mechanisms of RSV, drugs and drug candidates, have shown great potential for clinical application.

View Article and Find Full Text PDF

Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy.

J Muscle Res Cell Motil

January 2025

Institute of Developmental and Regenerative Medicine, University of Oxford, IMS-Tetsuya Nakamura Building, Old Road Campus, Roosevelt Dr, Headington, Oxford, OX3 7TY, UK.

Recent years have seen enormous progress in the field of advanced therapeutics for the progressive muscle wasting disease Duchenne muscular dystrophy (DMD). In particular, four antisense oligonucleotide (ASO) therapies targeting various DMD-causing mutations have achieved FDA approval, marking major milestones in the treatment of this disease. These compounds are designed to induce alternative splicing events that restore the translation reading frame of the dystrophin gene, leading to the generation of internally-deleted, but mostly functional, pseudodystrophin proteins with the potential to compensate for the genetic loss of dystrophin.

View Article and Find Full Text PDF

Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic syndrome involving urinary frequency, urgency, and bladder discomfort. These IC/BPS symptoms can significantly impact individuals' quality of life, affecting their mental, physical, sexual, and financial well-being. Individuals sometimes rely on peer-to-peer support to understand the disease and find methods of alleviating symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!